Capital PEC Report Project ID: 300762705

Project Name VACAVILLE GRASSROOT FILL/FINISH PROTEIN-BASED ANTI CANCER

Industry Code 13 Pharmaceutical & Biotech Project Type Grassroot

TIV (USD) 80.000.000

SIC Code 2836 Biological Products, Except

Diagnostic Substances

Sector Final Formulation (Oral. Solid, Parenteral, Topical, PEC Activity Diagram

etc.)

SIC Product 2836*0036 Aseptic Fill and Finish - Ampoules, Cartridges, Syringes, Vials

Status Active Last Update 31-Jan-2022 Initial Release 27-Jan-2022

Environmental Air (A) Land (L) Water (W)

Construction Labor Preference Union, Non-Unior

Plant Parent Polaris Group Limited

Phone +1 707 451 0441

Operations Labor Preference Non-Union

Plant Owner Polaris Pharmaceuticals

Incorporated

Plant Name Vacaville Fill/Finish/Protein-Based

Anti Cancer CDMO

Plant ID 3493136

Location Intersection of Interstates 80 and

A&E CRB Engineering Incorporated

Emeryville, California 94608

6001 Shellmound Street Suite 550

505, Vaca Valley Business Park

Unit Name

City/State Vacaville, California 95688 U.S.A. Zone/County CA*03, Solano **Project Responsibility Project Company Project Contact** Project Director Polaris Pharmaceuticals Incorporated Chris Huxsoll **VP** Operations 4941 Allison Parkway Vacaville, California 95688 [Tel.] +1 707 451 0441 x112 / [Alt.] +1 530 902 4848 (Mobile) U.S.A. [E-Mail] chuxsoll@polarispharma.com; [LinkedIn] chris-huxsoll-555a631 Project Manager Polaris Pharmaceuticals Incorporated Matt Mitchell 4941 Allison Parkway Director of Facilities Vacaville, California 95688 [Tel.] +1 707 451 0441 x103 / [Alt.] +1 707 724 2760 (Mobile) U.S.A. [E-Mail] mmitchell@polarispharma.com; [LinkedIn] mitchellcon Specification and Reliability Polaris Pharmaceuticals Incorporated **Daniel Wood** 4941 Allison Parkway Senior Production Manager Vacaville, California 95688 [Tel.] +1 707 451 0441 [E-Mail] dwood@polarispharma.com : [LinkedIn] U.S.A. daniel-wood-861229209

PEC® Timing P1

PEC® Activity Preliminary Design

Trevor Auer

Project Manager

[Tel.] +1 510 907 2701

trevor-auer-3b24376

[E-Mail] trevor.auer@crbgroup.com; [LinkedIn]

Project Probability Medium (70-80%)

U.S.A.

Scope Polaris Pharmaceuticals Incorporated with CRB Engineering Incorporated (Conceptual Architect) performs Preliminary Design for Grassroot Fill/Finish & Protein Based Anti-Cancer Therapeutics CDMO Plant, DETAILS: Within Vaca Valley Business Park, near the intersection of Interstates 80 and 505, on recently purchased (from Agenus) 15-acre site, construct building(s) (size tobe-determined) and equip for the proprietary and contract R&D, QC and production of protein-based novel anti-cancer therapies (including the proprietary Pegargiminase ADI-PEG 20, which is in late-stage clinical development) plus temperature controlled warehouse. REQUIRES: Building(s), Building Management Systems (BMS), Building Automation Systems (BAS), Temperature and Humidity Controls, Fire and Security System, Air/Gas Vacuum System, Refrigeration, Freezers, Conveyors (Belt/Roller), Industrial Gas Supply and Storage, Voice/Data/Wireless System, Fermentation Equipment, Centrifuges. Microfluidizers, Harvest & Holding Vessels, Buffer Preparation Tanks, Chromatography Skids, Tangential Flow Filtration (TFF) Systems, Aseptic Fill/Finish Equipment (Vials), Visual Inspection Equipment, Cleanrooms (ISO 5-7/Class 100-10,000), Cell Lysis Equipment, Water-For-Injection System, Laboratory Stations, Analytical Equipment, Data Recorders, Checkweighers, Automated Clean-In-Place Skids, High Purity Piping, Clean Steam Generators, Compressors (Air), Material Handling Equipment, Automated Retrieval Systems, Controls (PLC, DCS), NGF Boiler, Chiller, Cooling Tower, Heat Exchangers, Electrical Distribution, Water Purification System, Emergency Generators, Uninterrupted Power Supply, Pumps, Motors, Valves. ENVIRONMENTAL: (A) HEPA Filtration System, Fume Hoods, Dust Collectors; (L) Containment; (W) Pre-Wastewater Treatment System, Stormwater Drainage System.

TRIALS; SHOULD HAVE RESULTS BY LATE SUMMER EARLY FALL 2022. TIV AND PROJECT CONSTRUCTION/BID AND

Schedule Polaris Pharmaceuticals Incorporated with CRB Engineering Incorporated (Conceptual Architect) continues with Preliminary Design through 3Q22 (Aug). Upon FDA approval of Pegargiminase ADI-PEG 20 (In Phase III clinical-trials), Polaris awards principal A/E 3Q22 (Aug-Sep). Upon substantial completion of Design, Polaris with A/E selects G/C 1Q23 (Jan-Mar). Upon selection Polaris with G/C releases any remaining Equipment RFQs plus Subcontractor Bid Documents 1Q23 (Mar)-2Q24 (Jun). Tentative Construction Kick-Off 2Q23 (Apr). Project Completion 4Q24 (Dec). **NOTE: THERE IS A PAUSE IN THIS PROJECT. POLARIS IS AWAITING FDA APPROVAL FOR PEGARGIMINASE ADI-PEG 20 THAT IS IN PHASE III CLINICAL

VENDOR SELECTION TIMELINES ARE ESTIMATED.**

AFE 202208 Sub Bid Doc 202303 Completion 31-Dec-2024 **Precision YEAR** Project Milestones Equip RFQ 202303 Kick-Off 202304 **Kickoff Slippage 4 Months Duration 21 Months**

Engineering Civil Electrical **Environmental HVAC** Instrumentation Mechanical Structural Process

Contracting Civil **Environmental HVAC** Instrumentation Mechanical Structural General Electrical [G/C] Project Key Needs Civil/Site Structural Architectural Control Room Process Equip Heat Transfer Storage Instrumentation Electrical Mechanical **HVAC** Piping/Fittings Insulation/Coatings Environmental Utilities Valves Communications Batch Packaging Process Material Handling **Matter Phase** Solid Liquid Energy Boiler Generator Buy Sell

Plant Standard Contacts					
Functional/Actual Title	Contact Name/E-mail	Telephone/On-site	QC Date/LinkedIn ID		
Plant Manager	Chris Huxsoll	[Phn.] +1 707 451 0441 x112 / [Alt.] +1 530 902 4848 (Mobile)	Jan-2022		
VP Operations	chuxsoll@polarispharma.com	No	chris-huxsoll- 555a631		

Historical Reports			
Project Name	Report Date	TIV	Phase
VACAVILLE GRASSROOT FILL/FINISH PROTEIN-BASED ANTI CANCER THERAPEUTIC CDMO PLANT	27-Jan-2022	80,000,000 USD	Preliminary Design (P1 -
VACAVILLE GRASSROOT FILL/FINISH PROTEIN-BASED ANTI CANCER THERAPEUTIC CDMO PLANT	28-Jan-2022	80,000,000 USD	Preliminary Design (P1 -
VACAVILLE GRASSROOT FILL/FINISH PROTEIN-BASED ANTI CANCER THERAPEUTIC CDMO PLANT	28-Jan-2022	80,000,000 USD	Preliminary Design (P1 -
VACAVILLE GRASSROOT FILL/FINISH PROTEIN-BASED ANTI CANCER THERAPEUTIC CDMO PLANT	31-Jan-2022	80,000,000 USD	Preliminary Design (P1 -

© 2022 ALL RIGHTS RESERVED. Industrial Info Resources, Inc. - Sugar Land, TX - 800-762-3361